人多能干细胞制造心肌细胞的研究进展。

IF 7.6 2区 工程技术 Q1 CHEMISTRY, APPLIED Annual review of chemical and biomolecular engineering Pub Date : 2022-06-10 DOI:10.1146/annurev-chembioeng-092120-033922
Martha E Floy, Fathima Shabnam, Aaron D Simmons, Vijesh J Bhute, Gyuhyung Jin, Will A Friedrich, Alexandra B Steinberg, Sean P Palecek
{"title":"人多能干细胞制造心肌细胞的研究进展。","authors":"Martha E Floy,&nbsp;Fathima Shabnam,&nbsp;Aaron D Simmons,&nbsp;Vijesh J Bhute,&nbsp;Gyuhyung Jin,&nbsp;Will A Friedrich,&nbsp;Alexandra B Steinberg,&nbsp;Sean P Palecek","doi":"10.1146/annurev-chembioeng-092120-033922","DOIUrl":null,"url":null,"abstract":"<p><p>The emergence of human pluripotent stem cell (hPSC) technology over the past two decades has provided a source of normal and diseased human cells for a wide variety of in vitro and in vivo applications. Notably, hPSC-derived cardiomyocytes (hPSC-CMs) are widely used to model human heart development and disease and are in clinical trials for treating heart disease. The success of hPSC-CMs in these applications requires robust, scalable approaches to manufacture large numbers of safe and potent cells. Although significant advances have been made over the past decade in improving the purity and yield of hPSC-CMs and scaling the differentiation process from 2D to 3D, efforts to induce maturation phenotypes during manufacturing have been slow. Process monitoring and closed-loop manufacturing strategies are just being developed. We discuss recent advances in hPSC-CM manufacturing, including differentiation process development and scaling and downstream processes as well as separation and stabilization.</p>","PeriodicalId":8234,"journal":{"name":"Annual review of chemical and biomolecular engineering","volume":"13 ","pages":"255-278"},"PeriodicalIF":7.6000,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197878/pdf/nihms-1800287.pdf","citationCount":"2","resultStr":"{\"title\":\"Advances in Manufacturing Cardiomyocytes from Human Pluripotent Stem Cells.\",\"authors\":\"Martha E Floy,&nbsp;Fathima Shabnam,&nbsp;Aaron D Simmons,&nbsp;Vijesh J Bhute,&nbsp;Gyuhyung Jin,&nbsp;Will A Friedrich,&nbsp;Alexandra B Steinberg,&nbsp;Sean P Palecek\",\"doi\":\"10.1146/annurev-chembioeng-092120-033922\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The emergence of human pluripotent stem cell (hPSC) technology over the past two decades has provided a source of normal and diseased human cells for a wide variety of in vitro and in vivo applications. Notably, hPSC-derived cardiomyocytes (hPSC-CMs) are widely used to model human heart development and disease and are in clinical trials for treating heart disease. The success of hPSC-CMs in these applications requires robust, scalable approaches to manufacture large numbers of safe and potent cells. Although significant advances have been made over the past decade in improving the purity and yield of hPSC-CMs and scaling the differentiation process from 2D to 3D, efforts to induce maturation phenotypes during manufacturing have been slow. Process monitoring and closed-loop manufacturing strategies are just being developed. We discuss recent advances in hPSC-CM manufacturing, including differentiation process development and scaling and downstream processes as well as separation and stabilization.</p>\",\"PeriodicalId\":8234,\"journal\":{\"name\":\"Annual review of chemical and biomolecular engineering\",\"volume\":\"13 \",\"pages\":\"255-278\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2022-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197878/pdf/nihms-1800287.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual review of chemical and biomolecular engineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1146/annurev-chembioeng-092120-033922\",\"RegionNum\":2,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, APPLIED\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of chemical and biomolecular engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1146/annurev-chembioeng-092120-033922","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 2

摘要

在过去的二十年中,人类多能干细胞(hPSC)技术的出现为各种体外和体内应用提供了正常和患病人类细胞的来源。值得注意的是,hpsc来源的心肌细胞(hPSC-CMs)被广泛用于模拟人类心脏发育和疾病,并在治疗心脏病的临床试验中。hPSC-CMs在这些应用中的成功需要强大的、可扩展的方法来制造大量安全和有效的细胞。尽管在过去十年中,在提高hPSC-CMs的纯度和产量以及将分化过程从2D扩展到3D方面取得了重大进展,但在制造过程中诱导成熟表型的努力进展缓慢。过程监控和闭环制造策略才刚刚发展起来。我们讨论了hPSC-CM制造的最新进展,包括差异化工艺开发和规模化以及下游工艺以及分离和稳定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Advances in Manufacturing Cardiomyocytes from Human Pluripotent Stem Cells.

The emergence of human pluripotent stem cell (hPSC) technology over the past two decades has provided a source of normal and diseased human cells for a wide variety of in vitro and in vivo applications. Notably, hPSC-derived cardiomyocytes (hPSC-CMs) are widely used to model human heart development and disease and are in clinical trials for treating heart disease. The success of hPSC-CMs in these applications requires robust, scalable approaches to manufacture large numbers of safe and potent cells. Although significant advances have been made over the past decade in improving the purity and yield of hPSC-CMs and scaling the differentiation process from 2D to 3D, efforts to induce maturation phenotypes during manufacturing have been slow. Process monitoring and closed-loop manufacturing strategies are just being developed. We discuss recent advances in hPSC-CM manufacturing, including differentiation process development and scaling and downstream processes as well as separation and stabilization.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annual review of chemical and biomolecular engineering
Annual review of chemical and biomolecular engineering CHEMISTRY, APPLIED-ENGINEERING, CHEMICAL
CiteScore
16.00
自引率
0.00%
发文量
25
期刊介绍: The Annual Review of Chemical and Biomolecular Engineering aims to provide a perspective on the broad field of chemical (and related) engineering. The journal draws from disciplines as diverse as biology, physics, and engineering, with development of chemical products and processes as the unifying theme.
期刊最新文献
Reassessing the Standard Chemotaxis Framework for Understanding Biased Migration in Helicobacter pylori. Models for Decarbonization in the Chemical Industry. Introduction. Will Hydrogen Be a New Natural Gas? Hydrogen Integration in Natural Gas Grids. Fluid Ejections in Nature
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1